Targeting uPARAP Modifies Lymphatic Vessel Architecture and Attenuates Lymphedema
Circulation · 2025
DOI: 10.1161/circulationaha.124.072093 ↗Kurz gefasst
Fachartikel in der Zeitschrift Circulation, 2025. Verfasst von Fabrice Gucciardo und 19 weiteren Autor:innen. Beteiligte Einrichtung: From the Laboratory of Tumor and Development Biology, GIGA (F.G., A.L., S.P., F.B., E.I., S.B., J.D., L.B., A.P., C.M., M.G.-I., A.N.), University of…. Hauptthemen laut MEDLINE: Lymphatic Vessels, Lymphedema. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
BACKGROUND: Lymphedema is an incurable disease associated with lymphatic dysfunction that causes tissue swelling and fibrosis. We investigated whether lymphedema could be attenuated by interfering with uPARAP (urokinase plasminogen activator receptor-associated protein; Mrc2 gene), an endocytic receptor involved in fibrosis and lymphangiogenesis. METHODS: We generated mice with lymphatic endothelial cell (LEC)–specific uparap deficiency and compared them with constitutive knockout mice by applying a preclinical model of secondary lymphedema (SL). Computerized methods were applied for 2-dimensional and 3-dimensional image quantifications. Cellular effects of uPARAP deletion on lymphatic permeability were assessed by small interfering RNA–mediated silencing in human dermal LECs and a pharmacologic treatment targeting ROCK (Rho-associated coiled coil containing kinase), an established regulator of cell junctions. The uPARAP and vascular endothelial cadherin partnership was investigated through proximity ligation assay, coimmunoprecipitation, and immunostaining. An in silico model was generated to analyze the fluid-absorbing function of the lymphatic vasculature. To interfere with uPARAP, its downregulation was achieved in vivo through a gapmer approach. RESULTS: uparap deficiency mitigated several key pathologic features of SL, including hindlimb swelling, epidermal thickening, and the accumulation and size of adipocytes. In both global and LEC-conditional uparap -deficient mice, induction of SL led to a distinctive labyrinthine vasculature, defined herein by twisted and hyperbranched vessels with overlapping cells. This topology, mainly composed of pre–collecting vessels, correlated with reduced SL, but not with change in fibrosis, highlighting the importance of uPARAP in regulating LEC functions in a lymphedematous context. In vitro, uPARAP knockdown in LECs impaired vascular endothelial growth factor C–mediated endosomal trafficking of vascular endothelial cadherin and induced overlapping cell junctions. The pharmacologic inhibition of ROCK recapitulated cell superimposition in vitro and the labyrinthine vasculature in vivo with attenuated SL. Computational modeling of labyrinthine lymphatic vasculature supported the observation on their improved fluid-absorbing function in comparison with a normal hierarchic network. These data provide proof of concept of inducing a labyrinthine topology to treat SL. For therapeutic purposes, we validated the use of an anti-uPARAP gapmer to induce a labyrinthine vasculature and attenuate SL formation. CONCLUSIONS: Our findings provide evidence that downregulating uPARAP expression can induce a beneficial remodeling of lymphatic vasculature that attenuates lymphedema through a cell junction–based mechanism, offering a novel therapeutic pathway for lymphedema.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- From the Laboratory of Tumor and Development Biology, GIGA (F.G., A.L., S.P., F.B., E.I., S.B., J.D., L.B., A.P., C.M., M.G.-I., A.N.), University of Liège, Sart-Tilman, Belgium.
- Human Molecular Genetics, de Duve Institute, University of Louvain, Brussels, Belgium (P.B., M.V.).
- U1297-Institut des Maladies Métaboliques et Cardiovasculaires (I2MC), Institut National de la Santé et de la Recherche Médicale (INSERM), Université de Toulouse, France (F.M.).
- Biomechanics Research Unit Department, Skeletal Biology and Engineering Research Center, Department of Development and Regeneration, KU Leuven, Belgium (C.V., L.G.).
- Departments of Plastic and Reconstructive Surgery (C.N.), University of Liège, Sart-Tilman, Belgium.
- Radiotherapy-Oncology (F.L.), University of Liège, Sart-Tilman, Belgium.
ORCID-Profile: Fabrice Gucciardo, Alizée Lebeau, Florence Buntinx, Elitsa Ivanova, Pascal Brouillard, Jonathan Deroye, Florent Morfoisse, Claire Villette, Christophe Nizet, François Lallemand, Carine Munaut, Kari Alitalo, Liesbet Geris, Miikka Vikkula, Agnès Noel
Zitieren
APA
Gucciardo, F., Lebeau, A., Pirson, S., Buntinx, F., Ivanova, E., Blacher, S., Brouillard, P., Deroye, J., Baudin, L., Pirnay, A., Morfoisse, F., Villette, C., Nizet, C., Lallemand, F., Munaut, C., Alitalo, K., Geris, L., Vikkula, M., Gautier-Isola, M., & Noel, A. (2025). Targeting uPARAP Modifies Lymphatic Vessel Architecture and Attenuates Lymphedema. Circulation. https://doi.org/10.1161/circulationaha.124.072093
Vancouver
Gucciardo F, Lebeau A, Pirson S, Buntinx F, Ivanova E, Blacher S, et al. Targeting uPARAP Modifies Lymphatic Vessel Architecture and Attenuates Lymphedema. Circulation. 2025. doi:10.1161/circulationaha.124.072093
BibTeX
@article{Gucciardo2025,
author = {Gucciardo, Fabrice and Lebeau, Alizée and Pirson, Sébastien and Buntinx, Florence and Ivanova, Elitsa and Blacher, Silvia and Brouillard, Pascal and Deroye, Jonathan and Baudin, Louis and Pirnay, Alexandra and Morfoisse, Florent and Villette, Claire and Nizet, Christophe and Lallemand, François and Munaut, Carine and Alitalo, Kari and Geris, Liesbet and Vikkula, Miikka and Gautier-Isola, Marine and Noel, Agnès},
title = {Targeting uPARAP Modifies Lymphatic Vessel Architecture and Attenuates Lymphedema},
journal = {Circulation},
year = {2025},
doi = {10.1161/circulationaha.124.072093}
}
EUVIMED